U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H31NO3
Molecular Weight 357.4864
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Aroxybutynin

SMILES

CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)C2=CC=CC=C2

InChI

InChIKey=XIQVNETUBQGFHX-QFIPXVFZSA-N
InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H31NO3
Molecular Weight 357.4864
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

PubMed

PubMed

TitleDatePubMed
Tolterodine: a review of its use in the treatment of overactive bladder.
2001
Oxytrol approved for overactive bladder.
2003 Aug
Oxybutynin extended-release: a review of its use in the management of overactive bladder.
2004
[Urinary incontinence: anticholinergic treatment].
2004 Oct-Dec
High performance liquid chromatographic determination of oxeladin citrate and oxybutynin hydrochloride and their degradation products.
2005 Aug
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices.
2005 Mar 21
Intravesical treatments for painful bladder syndrome/ interstitial cystitis.
2007 Oct 17
Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
2007 Sep
Oxybutynin extended release for the management of overactive bladder: a clinical review.
2009 Sep 21
Application of oxybutynin selective sensors for monitoring the dissolution profile and assay of pharmaceutical dosage forms.
2010
Parasympathetic functions in children with sensory processing disorder.
2010
Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence.
2010 Sep 14
Patents
Substance Class Chemical
Created
by admin
on Sat Dec 16 19:33:23 UTC 2023
Edited
by admin
on Sat Dec 16 19:33:23 UTC 2023
Record UNII
5BRQ29UUB7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Aroxybutynin
INN  
Official Name English
(-)-OXYBUTYNIN
Common Name English
OXYBUTYNIN, (-)-
Common Name English
4-(diethylamino)but-2-yn-1-yl (R)-cyclohexyl(hydroxy)(phenyl)acetate
Systematic Name English
(R)-OXYBUTYNIN
Common Name English
Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, 4-(diethylamino)-2-butyn-1-yl ester, (αR)-
Systematic Name English
aroxybutynin [INN]
Common Name English
R-OXYBUTYNIN
Common Name English
OXYBUTYNIN, (R)-
Common Name English
Code System Code Type Description
FDA UNII
5BRQ29UUB7
Created by admin on Sat Dec 16 19:33:24 UTC 2023 , Edited by admin on Sat Dec 16 19:33:24 UTC 2023
PRIMARY
CAS
119618-21-2
Created by admin on Sat Dec 16 19:33:24 UTC 2023 , Edited by admin on Sat Dec 16 19:33:24 UTC 2023
PRIMARY
SMS_ID
300000045599
Created by admin on Sat Dec 16 19:33:24 UTC 2023 , Edited by admin on Sat Dec 16 19:33:24 UTC 2023
PRIMARY
INN
12152
Created by admin on Sat Dec 16 19:33:24 UTC 2023 , Edited by admin on Sat Dec 16 19:33:24 UTC 2023
PRIMARY
PUBCHEM
6098167
Created by admin on Sat Dec 16 19:33:24 UTC 2023 , Edited by admin on Sat Dec 16 19:33:24 UTC 2023
PRIMARY
NCI_THESAURUS
C190351
Created by admin on Sat Dec 16 19:33:24 UTC 2023 , Edited by admin on Sat Dec 16 19:33:24 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
RACEMATE -> ACTIVE ENANTIOMER
TARGET -> INHIBITOR
ENANTIOMER -> ENANTIOMER
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY